/

CTMX

CytomX Therapeutics, Inc.After hours

2.33−0.10 −3.93%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.34 +0.68%

Open

2.45

Prev close

2.42

Day range

2.322.45

52-week range

2.328.21

Volume

5.22M1.54×

Mkt cap

506.62M

P/E ttm

—

Fwd P/E

-4.94

EPS ttm

-0.5100

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−71.68%

Price Chart

Yahoo Finance · delayed

CTMXOct 13, 2026O 2.45H 2.45L 2.32C 2.33−0.10 (−3.93%)Vol 5.22M

SMA 503.10
SMA 2004.00

1Y change −30.80% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CTMX CytomX Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.18%
1 month: −29.33%
3 months: −36.48%
6 months: −48.79%
Year to date: −45.42%
1 year: −31.62%

Valuation & ownership

Market cap: 506.62M
Enterprise value: 202.74M
P/E (ttm): —
Forward P/E: -4.94
PEG ratio: —
Price / book: 1.68
Price / sales (ttm): 27.68
EV / EBITDA: -2.35
EPS (ttm): -0.5100
EPS (forward): -0.4702
Beta (5y monthly): 2.20
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 217.90M
Float: 179.66M
Short % of float: 21.25%
Short ratio (days): 9.26
Held by insiders: 0.57%
Held by institutions: 104.11%
Avg volume (3m): 3.39M
50-day average: 3.12
200-day average: 4.01
52-week change: −31.62%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 29.0
vs 50-day SMA: −25.07%
vs 200-day SMA: −41.84%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.99%
Realised vol (20d, ann.): 49.6%
From 52-week high: −71.68%
From 52-week low: +0.22%

ANR

Analyst Consensus

8 analysts

Consensus

Strong buy

1.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

12.25

+426.88% implied

Low 6.00Median 12.00High 16.00

Recommendation trend

Now8 / 0 / 0
1m ago8 / 0 / 0

DES

About CytomX Therapeutics, Inc.

Yahoo Finance profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 69
Headquarters: South San Francisco, CA, United States
Website: cytomx.com
Officers: Dr. Sean A. McCarthy DPHIL

SEAS

Seasonality · CTMX

2015–2026 · monthly returns

Strongest month May +19.43%Weakest month Oct −6.99%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	33.6	-5.6	-12.5	-10.2	-14.7	4.2	-17.3	8.4	-19.0	-14.5			−45.4%
2025	-17.5	-20.4	-6.1	17.0	256.2	-14.3	-3.5	-6.8	56.4	11.9	19.9	-0.5	+313.6%
2024	-1.3	60.1	-11.0	-25.2	4.3	-28.2	13.1	-14.5	0.0	-15.6	6.4	-2.8	−33.5%
2023	68.8	-20.4	-29.8	7.9	4.9	0.6	1.2	-13.8	-14.0	-14.7	26.4	11.5	−3.1%
2022	6.2	-16.7	-30.3	-36.0	-5.8	13.7	-21.9	4.9	-3.3	-9.7	32.8	-8.0	−63.0%
2021	5.5	13.6	-1.5	21.1	-23.5	-11.6	-14.5	-5.4	-0.6	16.5	11.5	-34.5	−33.9%
2020	-10.7	-9.8	14.6	34.6	-14.1	-6.0	-15.8	4.1	-8.9	-0.5	13.6	-12.9	−21.2%
2019	12.5	-33.9	-4.2	-11.5	1.6	16.1	-8.1	-14.8	-15.9	-16.9	2.1	32.7	−45.0%
2018	26.7	11.1	-4.2	-7.6	-2.4	-10.9	15.2	-14.6	-17.7	-22.9	-3.2	9.4	−28.5%
2017	5.7	7.6	38.2	-9.0	-10.3	10.0	-13.0	28.1	5.2	10.1	3.5	2.0	+92.1%
2016	-24.7	-17.9	0.0	0.2	-16.4	-5.4	-1.5	16.6	33.7	-28.1	-1.2	-1.3	−47.3%
2015											84.7	8.6	+100.7%

INSD

Insider Activity · CTMX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

100K shares

Sells, 6 months

1.6K shares

Net shares

+98.4K

Net change in insider shares

+8.50%

Date	Insider	Transaction	Shares	Value
Aug 2, 2026	Carvajal Alejandra V.Officer	Stock Award(Grant) at price 0.00 per share.	100K	—
Jun 14, 2026	Ogden ChristopherChief Financial Officer	Sale at price 3.05 per share.	1.6K	$4.95K
Mar 16, 2026	Mccarthy Sean A.Chief Executive Officer	Sale at price 6.42 per share.	119K	$764.14K
Mar 16, 2026	Chu Yu-WayeOfficer	Sale at price 6.42 per share.	21.3K	$136.68K
Mar 16, 2026	Ogden ChristopherChief Financial Officer	Sale at price 6.42 per share.	19.3K	$124.11K
Mar 16, 2026	Belvin MarciaOfficer	Sale at price 6.42 per share.	31.5K	$202.27K
Feb 1, 2026	Mccarthy Sean A.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	210K	—
Feb 1, 2026	Chu Yu-WayeOfficer	Stock Award(Grant) at price 0.00 per share.	75K	—
Feb 1, 2026	Ogden ChristopherChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	90K	—
Feb 1, 2026	Belvin MarciaOfficer	Stock Award(Grant) at price 0.00 per share.	60K	—
Feb 1, 2026	Lester RachaelOfficer	Stock Award(Grant) at price 0.00 per share.	20K	—
Nov 5, 2025	Mccarthy Sean A.Chief Executive Officer	Sale at price 4.54 per share.	101.8K	$461.91K
Jun 15, 2025	Mccarthy Sean A.Chief Executive Officer	Sale at price 2.69 per share.	55.5K	$149.26K
Jun 15, 2025	Ogden ChristopherChief Financial Officer	Sale at price 2.69 - 2.95 per share.	12.3K	$33.38K
Jun 15, 2025	Belvin MarciaOfficer	Sale at price 2.69 per share.	13.9K	$37.33K
Jun 12, 2025	Mccarthy Sean A.Chief Executive Officer	—	150K	—
Jun 12, 2025	Ogden ChristopherChief Financial Officer	—	37.5K	—
Jun 12, 2025	Belvin MarciaOfficer	—	37.5K	—
Mar 17, 2025	Mccarthy Sean A.Chief Executive Officer	Sale at price 0.60 per share.	37.7K	$22.56K
Mar 17, 2025	Chu Yu-WayeOfficer	Sale at price 0.60 per share.	4K	$2.41K

CTMX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CTMX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CytomX Therapeutics, Inc.

Seasonality · CTMX

Insider Activity · CTMX

Congress Trades · CTMX

Investors Holding CTMX

Investors Holding CTMX

Congress Trades · CTMX

Insider Activity · CTMX

Seasonality · CTMX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CytomX Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News